Previous 10 | Next 10 |
home / stock / inrlf / inrlf news
Saint Herblain ( France), September 25 , 202 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced the signing of a new $32 million contract with the United States (U.S.) Department of Defense (DoD) for the supply of ...
2023-09-21 13:06:04 ET Valneva SE (VALN) Q2 2023 Earnings Conference Call September 21, 2023, 09:00 AM ET Company Participants Joshua Drumm - VP, IR Thomas Lingelbach - CEO Peter Buhler - CFO Conference Call Participants Maury Raycroft - Jefferies ...
Product sales more than doubled in the first half of 202 3 to €69.7 million compared to €33.3 million in the first half of 2022 Driven by IXIARO ® and DUKORAL ® sales, both of which benefited from a continued recovery...
S trong immune response shown in both children and adolescents one month after booster dose ( m onth 19) in VLA15-221 study P reviously observed high anamnestic antibody response in adults confirmed VLA15 well-tolerated in all ag...
Saint- Herb lain (France ) , August 31 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that members of its senior leadership team are scheduled to participate in 1-on-1 meetings with i...
Saint - Herblain ( France), August 29 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has completed screening validation of the Company’s regulatory application f...
Saint- Herb lain (France ) , August 28 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported positive initial Phase 3 safety data in adolescents for its single-dose chikungunya virus (CHI...
Up to an additional $100 million made available in two tranches Saint - Herblain ( France ), August 1 7 , 202 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced an agreement to incre...
Saint - Herblain ( France), August 14 , 2 02 3 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the U.S. Food and Drug Administration (FDA) has revised the Prescription Drug User Fee Act (PDUFA...
2023-07-18 04:17:27 ET Summary Positive Phase 3 data from Bavarian Nordic's chikungunya virus (CHIKV) vaccine candidate, PXVX0317, reinforces bullish view on Valneva's VLA1553 due to its superior clinical profile. Valneva's VLA1553 demonstrated impressive seroresponse rates and du...
News, Short Squeeze, Breakout and More Instantly...
Saint Herblain (France), July 1, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that the European Commission (EC) has granted marketing authorization in Europe for Valneva’s single-dose vaccine, IXCHIQ ® , for the p...
Saint-Herblain (France), June 26, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that all the resolutions recommended by the Board of Directors were approved by the shareholders at its Combined General Meeting (CGM) held today in L...
Saint-Herblain (France), June 24, 2024 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that Health Canada has approved IXCHIQ ® , Valneva’s single-dose vaccine for the prevention of disease caused by the chikungunya virus...